Due to the diverse nature of
its target, pain treatment warrants a wide range of options. The multitude of
analgesics available today and the several delivery methods devised for the
best patient care signify the growth and importance of the pain treatment market.
Pain management and treatment
deals with different levels of pain and over the years, options such as
pharmacotherapy, radiation, or physical therapy, or surgery have been used to
treat pain. Innovation is the key to the pain
treatment market and companies
have been consistently developing new and effective drugs to treat mild to
severe pain.
The active pipeline of pain treatment and management presently
holds more than 790 products at different stages of development. Competition in
the market is tough and even with the fact that the pain treatment market is
considerably mature, the truth is that science and medicine can never give up
on innovation. Developing new therapies that are less toxic, less addictive,
and more efficacious than existing medications is the challenge that players in
this market have to focus on to stay strong in the competition.
The significance of first-in-class drugs for pain treatment is
vital and presents increasing investment opportunities for drug manufacturing
companies. The pain treatment market, in general, has witnessed a lot of
activity over the past eight years, with 261 licensing deals and about 112
co-development deals. However, when it comes to first-in-class product deals,
the market has been relatively slow.
First-in-class, as the US FDA suggests, are drugs that use a
novel and unique method of action to treat a medical condition. A
first-in-class drug spells innovation and, though rewarding, can be extremely risky
and time-consuming. However, drug companies are willing to take this risk of
investment. Around 170 first-in-class products in the pain treatment market are
available for co-development and licensing deals. Some of these products have
been showcased in preclinical trials and have proven to provide high rewards
for investments.
Studies by MRRSE Research show that the market for pain
treatment is dominated by steroidal anti-inflammatory drugs and opioids and the
presence of novel products has been unable to challenge this dominance. In
2008, the number of patent applications for novel pain therapeutics was 4,970,
which dropped to 3,492 in 2012, presenting an average annual decline of 8%.
This signifies the unmet therapeutic needs when it comes to new methods of pain
treatment. However, this can be addressed by technological advances and
dedicated research efforts.
As mentioned earlier, the active pipeline of pain treatment
presently holds about 796 products at various phases of development presenting
an increased diversity of molecular targets. The 122 first-in-class projects in
active development stage form 13.6% of the overall pipeline, of which 65
first-in-class molecular targets reflect an increased level of innovation.
Big Pharma companies such as Novartis, Boehringer Ingelheim,
Sanofi, Allergan, and Merck & Co. are reportedly driving the pain treatment
and therapeutics market in the segment of innovation. Merck led the market
between 2008 in terms of patent grants, with 59 out of 142 patent applications being
granted. Boehringer Ingelheim was granted 35, Allergan received 34, while
Novartis and Sanofi received 30 each.
The pain treatment and management market is largely fragmented
and this poses an opportunity for new classes of drugs as numerous blockbuster
patents near expiration.
Table
of Contents
1 Table of Contents
1.1 List of Figures
2
Executive Summary
2.1 Large and Innovative Pipeline
2.2 Highly Diversified Range of Innovative Programs in Early
Pipeline and in Granted Patents
2.3 Active Deals landscape with Numerous Investment
Oppertunities
3 The
Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Development Remains
Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor
First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 MRRSE Research Report Guidance
4
Clinical and Commercial Landscape
4.1 Disease Overview
4.1.1 Chronic and Neuropathic Pain
4.1.2 Disease Pathophysiology
4.1.3 Diagnosis
4.1.4 Treatment Option
4.1.5 Treatment Algorithm
4.2 Overview of Marketed Products for Pain
4.2.1 Analgesic Product Categories
4.2.2 Molecular Type Analysis
4.2.3 Molecular Target Analysis
4.2.4 Current Unmet Needs
Send An
Enquiry : http://www.mrrse.com/enquiry/108
5
Assessment of Pipeline Product Innovation
5.1 Pain Pipeline by Molecule Type, Phase and Therapeutic
Targets
5.2 Comparative Distribution of Programs between the Pain Market
and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs
5.4 First-in-Class Targets by Pain Subtype
6 Pain
Patent Analysis
7
First-in-Class Target and Pipeline Program Evaluation
7.1 Pipeline Programs Targeting Fatty Acid Amide Hydrolase
7.2 Pipeline Programs Targeting Purinoceptor 3
7.3 Pipeline Programs Targeting Purinoceptor 7
7.4 Pipeline Programs Targeting Purinoceptor 4
7.5 Pipeline Programs Targeting Orexin Receptor Type 1
7.6 Pipeline Programs Targeting Neuronal Nitric Oxide Synthase
7.7 Pipeline Programs that Target Tropomyosin-Related Kinase A
7.8 Pipeline Programs that Target C-C Chemokine Receptor 2
7.9 Pipeline Programs that Target Endomorphin 2
7.10 Pipeline Programs that Target Protein Kinase C?
7.11 Pipeline Programs that Target Opioid Receptor-Like-1
Receptor
7.12 Pipeline Programs that Target Bradykinin B1 Receptor
7.13 Pipeline Programs Targeting Galanin Receptor 2
7.14 Pipeline Programs Targeting Nerve Growth Factor
8 Deals
and Strategic Consolidations
8.1 Industry Industry-wide First-in-Class Deals
8.2 Pain Deals Landscape
8.3 Licensing Deals
8.3.1 Molecule Type
8.3.2 Mechanism of Action
8.4 Co-development Deals
8.4.1 Molecule Type
8.4.2 Mechanism of Action
8.5 First-in-Class Programs Not Involved in Licensing or
Co-Development Deals
9
Appendix
9.1 Abbreviations
9.2 References
9.3 Contact Us
9.4 Disclaimer
Upcoming
Report :
· Salt Market - Global Industry Expert
Opinions Analysis, Emerging Opportunities, Market Size, Share, Growth Drivers,
Market Trends, Statistics And Forecast 2015 – 2020 http://www.mrrse.com/salt-market
Global salt production has
increased in 2013 after a decline in 2011 and 2012. The rise is attributed to
reviving demand from the road de-icing and chlor-alkali markets on account of
economic recovery in the U.S. and Europe.
Demand from the chemical sector, especially chlor-alkali and
soda ash industries, is expected to drive the salt market. Additionally, winter
demand from road de-icing market is another significant driver for salt market.
However, salt is a volatile material and the difficulty in transportation might
offset the market growth. New applications from the chemical sector are
expected to bring demand prospects for salt market.
·
Phosphate Minerals Market - Global Industry
Expert Opinions Analysis, Emerging Opportunities, Market Size, Share, Growth
Drivers, Market Trends, Statistics And Forecast 2015 – 2020 http://www.mrrse.com/phosphate-minerals-market
Phosphate minerals are minerals
containing tetrahedrally co-ordinated anions. The phosphate group of minerals
includes triphylite, monazite, pyromorphite, vanadinite, erythrite, lazulite,
turquoise, autunite, carnotite apatite group, etc. Phosphate minerals of
apatite group are generally mined from phosphate rocks. Main apatite mineral
types include, Collophane, Francolite, and Dahlite. Other phosphate bearing
minerals of economic significance are monazite, turquoise, and pyromorphite.
Phosphate deposits are classified in three main types namely, marine
sedimentary phosphorite, apatite-rich igneous rocks and guano accumulations.
Agriculture is the largest end-user industry of phosphate minerals. Phosphate
minerals are also used in food preservatives, animal feed, cosmetics,
fungicides, ceramics, metallurgy and water treatment. Production of fertilizers
is the major application for phosphate containing minerals. Phosphate minerals
are generally mined by surface mining. After removal of ore from the ground the
second stage of mining is the beneficiation process where the ore is separated
by using various chemicals reagents in order to extract pure minerals.
About Us
Market Research Reports Search Engine (MRRSE) is an
industry-leading database of market intelligence reports. Headquartered in New
York, U.S., MRRSE is driven by a stellar team of research experts and advisors
trained to offer objective advice. Our sophisticated search algorithm returns
results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to
provide clients single-point access to top-of-the-line market research. MRRSE’s
repository is updated every day to keep its clients ahead of the next new trend
in market research, be it competitive intelligence, product or service trends
or strategic consulting.
Contact
Us:
State
Tower,
90
State Street,
Suite
700,
Albany
NY - 12207
United
States
Tel:
+1-518-618-1030
Email:
sales@mrrse.com
Website:
http://www.mrrse.com/
No comments:
Post a Comment